First new systemic therapy in more than 15 years for cancer related to asbestos exposure Today, Bristol Myers Squibb Canada announced Health Canada's approval of OPDIVO ® 360 mg every three weeks or 3mgkg every two weeks plus YERVOY ® 1 mgkg every six weeks for the treatment of adult patients with unresectable malignant pleural mesothelioma who have not received prior systemic therapy for MPM. i This is the ...